Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Status:
Completed
Trial end date:
2015-03-11
Target enrollment:
Participant gender:
Summary
To compare the efficacy of treatment with a single dose of dalbavancin 1500 mg to treatment
with a two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8) in
participants with known or suspected Gram-positive acute bacterial skin and skin structure
infections (ABSSSI) at 48 -72 hours after initiation of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Durata Therapeutics Inc., an affiliate of Allergan plc